February 2024—From her vantage at the University of Texas MD Anderson Cancer Center, Donna Hansel, MD, PhD, has a clear view of cancer’s latest frontiers. Progress and breakthroughs are the norm. But even she sounds impressed when she surveys the changes in her specialty, urothelial cancer. “We are now thinking what we never before thought was possible: We are thinking about cures and lifelong remission from disease,” says Dr. Hansel, division head and professor of pathology and laboratory medicine. It’s been a long time coming, says Dr. Hansel, who is also the Dr. Eva Lotzova and Peter Lotz memorial research chair. The disease historically has been caught in a sort of prepositional triangle—underfunded, overlooked, and underdiagnosed—with serious consequences. For years, she says, “We thought bladder cancer had only one treatment”—BCG, or Bacillus Calmette-Guérin, therapy. Because the field lacked a large volume of research to propel better diagnostics and treatments, “people died of this disease because it progressed.”
Read More »FEBRUARY 2024
-
Doing more, doing better in bladder cancer
-
As AI use expands, ethics at the leading edge
February 2024—Artificial intelligence is sizzling, so much so that New Yorker magazine, evoking the dazzling and the potentially devouring nature of AI technology, tagged 2023 as “The Year A.I. Ate the Internet.”
-
Biomarker tests with discrepant results—why the differences?
February 2024—When multimodality testing reveals discordant biomarker results, which method is correct? Annette S. Kim, MD, PhD, and JinJuan Yao, MD, PhD, in a CAP23 session last fall used their cases to share strategies for resolving discrepancies—or, in some cases, what look like discrepancies.
-
With pipeline for pathologists, others lacking, eyes on AI
February 2024—Artificial intelligence and Medicare Advantage contracts were at the center of the Jan. 2 Compass Group virtual roundtable led by CAP TODAY publisher Bob McGonnagle. “If you want to get into the AI world, there are many lanes you can swim in,” said Michael Feldman, MD, PhD, of Indiana University School of Medicine.
Image Credits: [do_widget id=enhancedtextwidget-12].
Video Spotlight
-
Epredia Announces Launch of SlideMate Laser
SlideMate Laser is the latest addition to Epredia’s world-class portfolio of precision cancer diagnostics products and services that provide a seamless end-to-end laboratory workflow. SlideMate Laser can integrate into a range a workflows.
Learn more. Read More »
CAP TODAY Roundtables
-
With pipeline for pathologists, others lacking, eyes on AI
February 2024—Artificial intelligence and Medicare Advantage contracts were at the center of the Jan. 2 Compass Group virtual roundtable led by CAP TODAY publisher Bob McGonnagle. “If you want to get into the AI world, there are many lanes you can swim in,” said Michael Feldman, MD, PhD, of Indiana University School of Medicine.
Read More » -
AP and CP reporting—the needs, the caveats
-
Panelists on viscoelastic and other coag assays
-
Digital pathology and AI—drivers, budgets, and jobs
CAP TODAY WEBINARS
-
Register for our upcoming webinar
Liquid Biopsy and Concurrent Testing Strategies for Patients with Metastatic NSCLC Thursday, April 11, 2024, 12:00 PM–1:00 PM ET Webinar presenter Zin Htway, PhD Supervisor and Operations Manager, Anatomic Pathology as HCA, Los Robles Hospital and Medical Center, will discuss the impact of liquid biopsy and concurrent biomarker testing for the appropriate care of patients with NSCLC. Dr. Htway will review the potential benefits of integrating liquid biopsy with standard-of-care tissue testing on turnaround time and identification of patients with actionable biomarkers in metastatic NSCLC and explore patient case scenarios that demonstrate potential successes and implementation considerations for concurrent liquid biopsy integration in metastatic NSCLC.
Read More » -
Combining Clinical Signs and Symptoms with Histopathology for Definitive Diagnosis of Idiopathic Multicentric Castleman Disease (iMCD)
Webinar presenter Jade Neff, MD, PhD, Assistant Professor of Pathology, Duke University Medical Center, discusses Definitive Diagnosis of Idiopathic Multicentric Castleman Disease (iMCD), including the pivotal role that pathologists play in diagnosing iMCD, an elusive and debilitating disease that poses unique diagnostic challenges.
Image Credits: [do_widget id=enhancedtextwidget-12].
Clinical Chemistry
-
The race to keep pace with drug use changes
February 2024—Xylazine prevalence, lab-developed testing, and new technology are converging at Yale New Haven Health in a way that gives rise to questions, worry, and new hope for faster drug testing.
Read More » -
New guidance on lab analysis in diabetes
-
In some settings, alternatives to HbA1c acceptable
-
Turning questions to answers in drug testing
Cytopathology
-
Thoracic SMARCA4-deficient undifferentiated tumor
January 2024—Thoracic SMARCA4-deficient undifferentiated tumor (TSDUT), formerly known as SMARCA4-deficient thoracic sarcoma and SMARCA4-deficient thoracic sarcomatoid tumor, is a relatively newly defined entity with a distinct clinical history, morphology, immunohistochemical profile, molecular findings, and clinical behavior.
Read More » -
Bethesda System for Reporting Thyroid Cytopathology
-
Reporting urine cytology: how Paris 2.0 differs from 1.0
-
Cytopathology in focus: How to approach cytology of unknown primary
AMP Case Reports
-
AMP case report: Identification of multiple germline cancer predisposing gene variants in a single patient during tumor sequencing analysis
October 2023—Next-generation sequencing of tumor tissue has important implications in solid and hematologic malignancies because it can identify genomic variants that provide diagnostic, prognostic, and predictive information to guide clinical management. Variants identified on tumor sequencing can be classified as somatic (acquired after conception) or inherited through germline.
Read More » -
AMP case report: Lung micropapillary adenocarcinomas revisited
-
AMP case report: Small intragenic structural variants in SATB2-associated syndrome
-
AMP case report: A germline GATA2 c.121C>G (p.P41A) variant in a patient with an unusual acute promyelocytic leukemia
-
AMP case report: ETV6/FLT3 fusion gene detected in a patient with T-cell lymphoblastic lymphoma
FEBRUARY 2024
-
Doing more, doing better in bladder cancer
February 2024—From her vantage at the University of Texas MD Anderson Cancer Center, Donna Hansel, MD, PhD, has a clear view of cancer’s latest frontiers. Progress and breakthroughs are the norm. But even she sounds impressed when she surveys the changes in her specialty, urothelial cancer. “We are now thinking what we never before thought was possible: We are thinking about cures and lifelong remission from disease,” says Dr. Hansel, division head and professor of pathology and laboratory medicine. It’s been a long time coming, says Dr. Hansel, who is also the Dr. Eva Lotzova and Peter Lotz memorial research chair. The disease historically has been caught in a sort of prepositional triangle—underfunded, overlooked, and underdiagnosed—with serious consequences. For years, she says, “We thought bladder cancer had only one treatment”—BCG, or Bacillus Calmette-Guérin, therapy. Because the field lacked a large volume of research to propel better diagnostics and treatments, “people died of this disease because it progressed.”
Read More » -
As AI use expands, ethics at the leading edge
February 2024—Artificial intelligence is sizzling, so much so that New Yorker magazine, evoking the dazzling and the potentially devouring nature of AI technology, tagged 2023 as “The Year A.I. Ate the Internet.”
-
Biomarker tests with discrepant results—why the differences?
February 2024—When multimodality testing reveals discordant biomarker results, which method is correct? Annette S. Kim, MD, PhD, and JinJuan Yao, MD, PhD, in a CAP23 session last fall used their cases to share strategies for resolving discrepancies—or, in some cases, what look like discrepancies.
-
With pipeline for pathologists, others lacking, eyes on AI
February 2024—Artificial intelligence and Medicare Advantage contracts were at the center of the Jan. 2 Compass Group virtual roundtable led by CAP TODAY publisher Bob McGonnagle. “If you want to get into the AI world, there are many lanes you can swim in,” said Michael Feldman, MD, PhD, of Indiana University School of Medicine.
Image Credits: [do_widget id=enhancedtextwidget-12].
Video Spotlight
-
Epredia Announces Launch of SlideMate Laser
SlideMate Laser is the latest addition to Epredia’s world-class portfolio of precision cancer diagnostics products and services that provide a seamless end-to-end laboratory workflow. SlideMate Laser can integrate into a range a workflows.
Learn more. Read More »
CAP TODAY Roundtables
-
With pipeline for pathologists, others lacking, eyes on AI
February 2024—Artificial intelligence and Medicare Advantage contracts were at the center of the Jan. 2 Compass Group virtual roundtable led by CAP TODAY publisher Bob McGonnagle. “If you want to get into the AI world, there are many lanes you can swim in,” said Michael Feldman, MD, PhD, of Indiana University School of Medicine.
Read More » -
AP and CP reporting—the needs, the caveats
-
Panelists on viscoelastic and other coag assays
-
Digital pathology and AI—drivers, budgets, and jobs
CAP TODAY WEBINARS
-
Register for our upcoming webinar
Liquid Biopsy and Concurrent Testing Strategies for Patients with Metastatic NSCLC Thursday, April 11, 2024, 12:00 PM–1:00 PM ET Webinar presenter Zin Htway, PhD Supervisor and Operations Manager, Anatomic Pathology as HCA, Los Robles Hospital and Medical Center, will discuss the impact of liquid biopsy and concurrent biomarker testing for the appropriate care of patients with NSCLC. Dr. Htway will review the potential benefits of integrating liquid biopsy with standard-of-care tissue testing on turnaround time and identification of patients with actionable biomarkers in metastatic NSCLC and explore patient case scenarios that demonstrate potential successes and implementation considerations for concurrent liquid biopsy integration in metastatic NSCLC.
Read More » -
Combining Clinical Signs and Symptoms with Histopathology for Definitive Diagnosis of Idiopathic Multicentric Castleman Disease (iMCD)
Webinar presenter Jade Neff, MD, PhD, Assistant Professor of Pathology, Duke University Medical Center, discusses Definitive Diagnosis of Idiopathic Multicentric Castleman Disease (iMCD), including the pivotal role that pathologists play in diagnosing iMCD, an elusive and debilitating disease that poses unique diagnostic challenges.
Image Credits: [do_widget id=enhancedtextwidget-12].
Clinical Chemistry
-
The race to keep pace with drug use changes
February 2024—Xylazine prevalence, lab-developed testing, and new technology are converging at Yale New Haven Health in a way that gives rise to questions, worry, and new hope for faster drug testing.
Read More » -
New guidance on lab analysis in diabetes
-
In some settings, alternatives to HbA1c acceptable
-
Turning questions to answers in drug testing
Cytopathology
-
Thoracic SMARCA4-deficient undifferentiated tumor
January 2024—Thoracic SMARCA4-deficient undifferentiated tumor (TSDUT), formerly known as SMARCA4-deficient thoracic sarcoma and SMARCA4-deficient thoracic sarcomatoid tumor, is a relatively newly defined entity with a distinct clinical history, morphology, immunohistochemical profile, molecular findings, and clinical behavior.
Read More » -
Bethesda System for Reporting Thyroid Cytopathology
-
Reporting urine cytology: how Paris 2.0 differs from 1.0
-
Cytopathology in focus: How to approach cytology of unknown primary
AMP Case Reports
-
AMP case report: Identification of multiple germline cancer predisposing gene variants in a single patient during tumor sequencing analysis
October 2023—Next-generation sequencing of tumor tissue has important implications in solid and hematologic malignancies because it can identify genomic variants that provide diagnostic, prognostic, and predictive information to guide clinical management. Variants identified on tumor sequencing can be classified as somatic (acquired after conception) or inherited through germline.
Read More » -
AMP case report: Lung micropapillary adenocarcinomas revisited
-
AMP case report: Small intragenic structural variants in SATB2-associated syndrome
-
AMP case report: A germline GATA2 c.121C>G (p.P41A) variant in a patient with an unusual acute promyelocytic leukemia
-
AMP case report: ETV6/FLT3 fusion gene detected in a patient with T-cell lymphoblastic lymphoma